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ABSTRACT
Histone methyltransferase inhibitors (HMTis) and histone deacetylase inhibitors (HDACis) are reported to synergistically in-
duce the expression of latent human immunodeficiency virus type 1 (HIV-1), but studies have largely been performed with cell
lines. As specific and potent HMTis directed at EZH1 (enhancer of zeste 2 Polycomb repressive complex 2 subunit 1)/EZH2 are
now in human testing, we wished to rigorously test such an inhibitor in a primary resting T-cell model of HIV latency. We found
that GSK343, a potent and selective EZH2/EZH1 inhibitor, reduced trimethylation of histone 3 at lysine 27 (H3K27) of the HIV
provirus in resting cells. Remarkably, this epigenetic change was not associated with increased proviral expression in latently
infected resting cells. However, following the reduction in H3K27 at the HIV long terminal repeat (LTR), subsequent exposure to
the HDACi suberoylanilide hydroxamic acid or vorinostat (VOR) resulted in increases in HIV gag RNA and HIV p24 antigen
production that were up to 2.5-fold greater than those induced by VOR alone. Therefore, in primary resting CD4 T cells, true
mechanistic synergy in the reversal of HIV latency may be achieved by the combination of HMTis and HDACis. Although other
cellular effects of EZH2 inhibition may contribute to the sensitization of the HIV LTR to subsequent exposure to VOR, and to
increase viral antigen production, this synergistic effect is directly associated with H3K27 demethylation at nucleosome 1 (Nuc-
1). Based upon our findings, the combination of HMTis and HDACis should be considered for testing in animal models or clini-
cal trials.
IMPORTANCE
Demethylation of H3K27 mediated by the histone methyltransferase inhibitor GSK343 in primary resting T cells is slow, occur-
ring over 96 h, but by itself does not result in a significant upregulation of cell-associated HIV RNA expression or viral antigen
production. However, following H3K27 demethylation, latent viral expression within infected primary resting CD4 T cells is
synergistically increased upon exposure to the histone deacetylase inhibitor vorinostat. Demethylation at H3K27 sensitizes the
HIV promoter to the effects of an HDACi and provides a proof-of-concept for the testing of combination epigenetic approaches
to disrupt latent HIV infection, a necessary step toward the eradication of HIV infection.
Current antiretroviral therapy (ART) potently suppresses hu-man immunodeficiency virus type 1 (HIV-1) replication;
however, HIV infection persists (1, 2). The primary reservoir of
persistent infection is a small pool of latently infected resting cen-
tral memory CD4 T cells (3–5). This reservoir must be targeted
in any attempt to eradicate HIV-1 infection. Latent HIV infection
is defined as dormant, nonreplicating virus that can be recovered
following activation of the latently infected cell. However, a recent
study found that a single exposure to latency-reversing agents,
even a broad mitogenic signal, does not reverse latency universally
throughout a population of infected cells, thus suggesting the need
for serial and/or combination latency reversal strategies (6). As the
toxicities of global T-cell activation may be clinically unacceptable
(7), careful targeting of cellular pathways must be developed to
effectively disrupt HIV latency within safe and tolerable clinical
protocols.
The chromatin environment is critical for the establishment
and maintenance of latent HIV infection (8–10). Epigenetic mod-
ifications such as histone methylation and deacetylation appear to
play a role in maintaining HIV latency. Latent HIV-1 proviruses
display a defined nucleosomal structure featuring a key nucleo-
some near the transcription start site (11, 12), with local occu-
pancy of histone deacetylases (HDACs), deacetylated histones
(13–15), and methylated histones (16–20). HDAC inhibitors
(HDACis) have been extensively studied for their potential to re-
activate latent virus in cultured-cell models of latency, ex vivo in
resting CD4 T cells from patients, and in vivo in patients with
ART-suppressed viremia (21–32). However, in some model sys-
tems and assays, HDAC inhibition has been claimed to be insuf-
ficiently effective to reverse HIV latency in a clinically meaningful
way, and the use of combination latency reversal strategies has
been proposed (33–35). Currently, it is unclear which model sys-
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tem(s) will accurately predict the efficacy and safety of combina-
tion therapies in vivo.
PRC1 and PRC2, the Polycomb repressor group (PcG) protein
complexes, and heterochromatin protein 1 (HP1) constitute the
major histone methyltransferase (HMT) complexes that silence
chromatin (36). Histone methylation at the lysine tails of histones
H3 and H4 can have diverse effects, but generally, methylation of
histones contributes to gene silencing, while demethylation allows
gene expression. PcG complexes contribute to the conditional si-
lencing at many cellular promoters (37). The trimethylation of
histone H3 at lysine 27 is a silencing mark propagated by the
histone methyltransferase EZH2 (enhancer of zeste 2 Polycomb
repressive complex 2 subunit 2), which is a component of the
multisubunit Polycomb repressive complex PRC2. EZH2 inhibi-
tion can reactivate the latent HIV long terminal repeat (LTR) in
latent T-cell lines (18). The small-molecule inhibitor GSK343 is a
highly specific EZH2/EZH1 inhibitor (38) and effectively treats
B-cell lymphomas in murine models (39).
The use of a combination of drugs targeting different epige-
netic targets, HMTs and HDACs, has been proposed as a strategy
for latency reversal (35). We demonstrate for the first time in a
primary resting T-cell model of HIV latency that pretreatment
with the EZH2 inhibitor (EZH2i) GSK343 at levels sufficient to
induce demethylation of H3K27 at the critical HIV LTR nucleo-
some 1 (Nuc-1) site is associated directly with sensitization of the
HIV LTR to subsequent pharmacological exposures to the HDACi
vorinostat (VOR) and leads to enhanced proviral expression and
latency reversal beyond that achieved by VOR alone. This is the
first demonstration of an effective, clinically feasible approach for
the use of combination epigenetic therapies to more effectively
disrupt latent HIV infection.
MATERIALS AND METHODS
Cell Lines, PBMCs, and tissue culture reagents. The latently infected
cell lines 2D10 and J-89 were maintained in RPMI medium with L-glu-
tamine (Gibco, Life Technologies), 10% fetal bovine serum (FBS),
penicillin (100 IU/ml), and streptomycin (100 g/ml) in an incubator
at 37°C with 5% CO2. Peripheral blood mononuclear cells (PBMCs)
were isolated from the buffy coat of healthy donors by using Ficoll-
Hypaque (GE Healthcare, USA) gradient centrifugation. After wash-
ing, the cells were plated in RPMI complete medium supplemented
with human interleukin-2 (IL-2) (Peprotech, USA) at 10 U/ml and
incubated in a humidified incubator at 37°C with 5% CO2. Written
informed consent was obtained from all participants before study en-
rollment. Approval was obtained from the University of North Caro-
lina (UNC) institutional biomedical review board and the Food and
Drug Administration.
Reagents used for proviral activation. GSK343 was a gift from P.
Trojer (Constellation Pharmaceuticals, Cambridge, MA). UNC 1999 was
a gift from J. Jian (Icahn School of Medicine at Mount Sinai, New York,
NY). VOR was a gift from Merck, phytohemagglutinin (PHA) was ob-
tained from Remel (Thermo Scientific, Waltham, MA), and JQ1 was a gift
from J. Bradner (Dana-Farber Cancer Institute, Harvard University).
Establishment of a primary cell model of HIV latency. Primary cell
experiments were performed as described previously by Saleh et al. (40),
with minor modifications. Experiments were repeated for confirmation at
least three times, using primary cells from the same donor. Briefly, frozen
PBMCs from a single healthy donor were thawed and kept overnight in
RPMI medium with L-glutamine, 10% FBS, penicillin (100 IU/ml), strep-
tomycin (100 g/ml), and 10 U IL-2 in 5% CO2 at 37°C. They were then
used to purify naive CD4 T cells by using naive CD4 T-cell isolation kit
II (Miltenyi Biotech) according to the manufacturer’s protocol. After pu-
rification, cells were maintained in medium supplemented with 50 nM
CCL19 (chemokine [C-C motif] ligand 19) for 2 days. These cells were
then washed and infected with NL4-3 virus (100 ng p24 viral equivalents
per million cells) by spinoculation for 2 h at 300  g at 37°C. After infec-
tion, cells were washed three times, resuspended in complete medium
with 10 U IL-2, and cultured for 4 days.
On day 4, infected cells were either treated with 2 M GSK343 or
left untreated for a further 96 h (to day 8). On day 8, equal numbers of
EZH2i-treated and untreated T cells were pulsed with 500 nM VOR for
24 h. As a positive comparative control, other cells were treated with 2
g/ml PHA for 24 h, and at days 9 and 12 after infection, viral expres-
sion and release were assessed by PCR of cell-associated RNA and a p24
enzyme-linked immunosorbent assay (ELISA) of the culture superna-
tant. Latently infected cells were harvested for chromatin immunopre-
cipitation (ChIP) analysis on day 4 prior to GSK343 treatment and on
day 8 after GSK343 treatment but prior to VOR pulsing. Supernatants
were collected on days 0, 4, 8, 9, and 12 and stored at 80°C until p24
ELISAs (ABL Inc., Rockville, MD) were performed. The efficiency of
infection varied from 3 to 10% in these experiments, and the cells were
noncycling throughout the experiment, as observed by carboxyfluo-
rescein succinimidyl ester (CFSE) labeling in the presence of 1 U/ml or
10 U/ml of IL-2 (data not shown).
ChIP. A ChIP assay kit (catalog number 17-295; Millipore) was
used, according to the manufacturer’s protocol. To obtain sheared
chromatin with DNA of 200 to 500 bp in length, extracted chromatin
from 1  106 cells per ChIP was sonicated by using a Diagenode
Bioruptor standard sonicator with a 1.5-ml tube holder at a medium
setting for 24 min (30 s on and 15 s off). ChIP was performed as
described above, with the following modifications. Sonicated cell ly-
sates were centrifuged, and 7 to 20 g of soluble chromatin was incu-
bated with 4 to 5 g antibody overnight. The following antibodies were
used: anti-histone H3, anti-H3K27me3 (trimethylated histone 3 at
lysine 27), anti-RNA polymerase II (Pol II), and anti-hemagglutinin
(HA) (Abcam); anti-EZH2, anti-H3K27me2, anti-EED (embryonic
ectoderm development gene), anti-RING1B, anti-BMI1, anti-
H3K27ac, and anti-phospho-Ser2 Pol II (Active Motif); anti-
H3K9me3 and anti-H3Ac (Millipore); and anti-HA, anti-rabbit, and
anti-mouse immunoglobulin G (Cell Signaling). A quantitative real-
time PCR assay of the products of ChIP was performed to verify the
significance of changes in the occupancy of the specific proteins at the
HIV-1 LTR with the use of Nuc-0, Nuc-1, Gag, and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) primers, as reported previously
(18). The sequences of primers are mentioned in Table S1 in the sup-
plemental material. The percentage of input HIV LTR DNA recovered
was determined by comparing the cycle threshold values of each reac-
tion to a standard curve generated from input DNA. The fold change in
occupancy of each protein at the LTR relative to the untreated control
was calculated after subtracting background immunoprecipitation
measured with nonspecific IgG or with an unrelated HA antibody.
Immunoblotting. A total of 1.5  106 2D10 cells, J-89 cells, or PBMCs
in 4 ml of RPMI medium were either untreated or treated with 0.25 M,
0.5 M, 1 M, and 2 M GSK343 for 96 h or kept with dimethyl sulfoxide
(DMSO) as a vehicle control. Cells were washed twice with phosphate-
buffered saline (PBS) and lysed in 200 l of radioimmunoprecipitation
assay (RIPA) buffer (20 mM Tris-HCl [pH 8.1], 1% Triton X-100, 2 mM
EDTA, 500 mM NaCl) with freshly added 1% protease inhibitor cocktail
and phosphatase inhibitor cocktail. Cells were incubated on ice for 10 min
with intermittent vortexing. DNA was removed by centrifugation at
13,000 rpm for 10 min at 4°C. Protein was quantified by using the Brad-
ford assay (41), and 20 to 25 g of total protein was analyzed by SDS-
PAGE. The following antibodies were used: primary anti-rabbit histone
H3 and anti-rabbit H3K27me3 (Cell Signaling), anti-mouse alpha-tubu-
lin (Abcam), and secondary anti-mouse-HRP (Sigma) and anti-rabbit-
HRP (Santa Cruz Biotechnology). These antibodies were used at the spec-
ified dilutions, according to the manufacturers’ instructions, with 5%
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milk or 5% bovine serum albumin (BSA) in 1 Tris-buffered saline (TBS)
containing 0.1% Tween 20.
Cell-associated viral RNA (green fluorescent protein [GFP] mRNA
or Gag RNA measurements). 2D10 cells, J-89 cells, or cells from the pri-
mary cell model were left untreated or treated with the selected drug
concentrations mentioned below. Cells were washed, snap-frozen in an
ethanol dry ice bath, and stored at 80°C until use. Cells were thawed on
ice, and RNA was isolated by using the RNeasy RNA isolation kit (Qiagen,
Valencia, CA) according to the manufacturer’s protocol. DNA was re-
moved from RNA extracts by DNase digestion (Promega, Madison, WI),
and cDNA was synthesized by using the SuperScript III first-strand syn-
thesis kit for reverse transcription-PCR (RT-PCR) (Invitrogen). Quanti-
tative PCR was performed on cDNA with a Bio-Rad CFX96 or CFX384
system using QuantiTect Multiplex PCR Mastermix (Qiagen). The se-
quences of primers and probes are mentioned in Table S1 in the supple-
mental material. The relative mRNA expression level was calculated by
using the 2CT method. The data shown are the means from at least
three independent experiments, and the error bars represent the standard
errors of the means.
MTT cell proliferation and viability assay. To measure the prolifera-
tion and viability of 2D10 cells, J-89 cells, PBMCs, or primary resting T
cells in the presence of compounds, cells were assayed by using the Vy-
brant 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bro-
mide (MTT) cell proliferation assay kit according to the manufacturer’s
instructions (Life Technologies). The percent viability over time was cal-
culated relative to untreated samples.
shRNA constructs and infections. Glycerol stocks carrying short
hairpin RNA (shRNA) inserted into the pLKO.1 backbone (vector) (cat-
alog number RHS4080; EZH2 clone TRCN0000040074) were obtained
from Open Biosystems. Silenced 2D10 cell populations carrying HIV-1
proviruses encoding a d2EGFP (enhanced green fluorescent protein de-
stabilized by residues 422 to 461 of mouse ornithine decarboxylase, giving
an in vivo half-life of 2 h) marker (i.e., 5% of cells in the unstimulated
cell population had detectable d2EGFP expression) were either superin-
fected with lentiviral vectors expressing either control or EZH2 shRNAs or
transfected with either control scrambled shRNA or EZH2 shRNA con-
structs by using the Mirus Jurkat Trans-IT transfection reagent according
to the manufacturer’s instructions. One million 2D10 cells were infected
with vesicular stomatitis virus glycoprotein (VSV-G)-pseudotyped lenti-
viral vectors expressing shRNAs. Cell viability and d2EGFP expression
were assessed via fluorescence-activated cell sorting (FACS).
Statistical analysis. Microsoft Excel or GraphPad Prism software was
used to analyze the data. The Student paired t test was used for data
analysis in pairs. In some experiments, one-way analysis of variance
(ANOVA) was performed for multiple data comparisons. A P value of
0.05 was considered statistically significant.
RESULTS
PRC1 and PRC2 occupy the HIV promoter in 2D10 cells. The
Polycomb repressive complexes PRC1 and PRC2 act to compact
chromatin but contain distinct components (37). The histone
methyltransferase EZH2 is the catalytic component of the PRC2
silencing complex. We sought to document the presence of PRC2
in the 2D10 cell line. This clonal model of HIV latency is derived
from Jurkat CD4 T cells harboring a single copy of the integrated
proviral genome with highly restricted expression, containing de-
letions in the HIV gag region and pol region and a mutation
(H13L) in the tat gene encoding a short-lived green fluorescent
protein (d2EGFP) reporter protein in place of the Nef gene (42).
ChIP assays were performed on 2D10 cell extracts to measure the
occupancy of key components of Polycomb repressive complexes
at the HIV-1 LTR. EZH2 and trimethylated histone 3 at lysine 27
(H3K27me3) were found at the HIV Nuc-1 region, as previously
shown in a related model (18), and occupancy of the PRC2 core
component EED was observed. Furthermore, RING1B and BMI1,
two core components of PRC1, were also detectable at the HIV-1
promoter (Fig. 1).
The loss of the H3K27me3 mark induced by exposure to
GSK343 has a negligible effect on proviral expression. EZH2 is
an HMT specifically involved in the di- and trimethylation of
histone H3 at lysine 27. To assess the kinetic effects of the EZH2i
GSK343 on the trimethylation of H3K27, 2D10 cells were treated
with 0.25 to 2.0 M GSK343 for up to 96 h. No overt toxic effects
were observed, and viability, as measured by an MTT assay, was
unaffected (see Fig. S2A in the supplemental material). Total cel-
lular trimethylated H3K27 was reduced in a time- and dose-de-
pendent manner, first discernible at 48 h (not shown) and maxi-
mally reduced at 96 h (Fig. 2A), without a change in the quantity of
total histone H3. More specifically, in concert with this decrease,
the measured occupancy of H3K27me3 at the HIV-1 LTR Nuc-1
site was not detectably reduced at 48 h (not shown) but was mark-
edly reduced at 96 h (Fig. 2B). The effect was specific, as the
H3K9me3 mark at the LTR remained unchanged (Fig. 2B). Fur-
thermore, H3K27me2, EED, and EZH2 occupancy at the HIV
LTR, determined by ChIP, and their total protein levels, detected
by immunoblotting, were unchanged (data not shown). In paral-
lel with H3K27me3 reduction, a modest increase in acetylated
histone H3 and an appreciable increase in acetylation at the spe-
cific lysine H3K27 were also seen (Fig. 2C). Moreover, the cellular
promoters for the heterochromatic gene SAT2 and the euchro-
matic gene MyoD also displayed reductions in the H3K27me3
mark, confirming a global cellular effect of GSK343 (Fig. 2D). To
confirm that these epigenetic effects were not unique to the
viral integrant found in 2D10 cells, the effects of GSK343 were
tested in J-89 cells, a cell line containing full-length provirus
with a gfp reporter gene followed by the env gene (43), where a
similar specific loss of total cellular H3K27me3 was seen, as was
reduced occupancy of this mark at the Nuc-1 region of the HIV
LTR (see Fig. S1A and S1B in the supplemental material).
Critically, despite the reduction in trimethylation at the HIV
FIG 1 Components of Polycomb repressive complexes 1 and 2 occupy the
HIV promoter in 2D10 cells. As expected, histone H3 occupancy was detected
at the HIV LTR Nuc-1 region, but occupancy of the p50 homodimer of NF-	B
was low or absent. Occupancy of the PRC2 components EZH2 and EED,
occupancy of the PRC1 components RING1 and BMI1, H3K27me2, and
H3K27me3 were detected; Results were compared with results for control IgG
by using Student paired t tests. Error bars represent standard errors of the
means (n 
 3). *, P  0.05; NS, not significant (P  0.05).
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LTR, we observed negligible increases in LTR-driven RNA pro-
duction and GFP expression levels following GSK343 treatment at
concentrations of up to 2 M for up to 96 h (Fig. 2E and F). This
is of mechanistic interest, as in concert with reduced trimethyla-
tion, increased acetylation at the same residue was seen (Fig. 2D).
It is therefore even more striking that no increase in LTR expres-
sion was seen, given the induction of expression seen in concert
with histone acetylation when induced by HDAC inhibitors (Fig.
2F). A similar lack of an effect on LTR-driven gag RNA or GFP
production was also seen in the J-89 model system (see Fig. S1C
and S1D in the supplemental material). Moreover, another selec-
tive EZH2 inhibitor, UNC 1999 (44), had similar effects on pro-
viral expression (data not shown).
EZH2 knockdown reduces H3K27me3 and PRC1 and PRC2
component occupancy without an increase in provirus expres-
sion. To examine the impact of EZH2 inhibition by using an
alternative approach, expression of EZH2 was inhibited by
EZH2-specific shRNAs (Fig. 3A). EZH2 gene silencing was ca.
70% effective in 2D10 cells compared to the control scrambled
shRNA. To directly address the role of EZH2 knockdown in
FIG 2 The EZH2 inhibitor GSK343 reduces trimethylated H3K27 in 2D10 cells but has a negligible effect on proviral expression. (A) Western blot showing global
reduction in H3K27me3 protein levels in whole-cell lysate after cells were treated with different concentrations of GSK343 for 96 h. The reported 50% inhibitory
concentration of GSK343 in the cancer cell lines tested was 0.2 M (38), so a range of concentrations of GSK343 of 0.25 to 2.0 M, starting close to its 50%
inhibitory concentration, was used to determine the drug effect. Histone H3 and -tubulin are shown as loading controls. (V, vehicle control [0.02% DMSO]).
(B) ChIP at the HIV LTR Nuc-1 promoter for H3K27me3 and H3K9me3. Hemagglutinin antibody (HA) is an unrelated isotype control. (C) Corresponding
changes in total H3 acetylation and in acetyl H3K27. ChIP panels were normalized to H3 levels. The H3 level did not significantly change between the control and
treated conditions. Results were compared with those for cells treated with the vehicle control DMSO by using Student paired t tests. Error bars represent
standard errors of the means (n 
 3). ● or *, P  0.05. (D) ChIP changes in H3K27me3 at the cellular promoters SAT2 (heterochromatic gene) and MyoD
(euchromatic gene) in cells treated with 0.5 M GSK343 for 96 h. *, P  0.05, from 3 pairs of assays (determined by a Student paired t test). Results were compared
to those of the respective DMSO controls (V, vehicle control). (E) Relative fold changes of cell-associated GFP RNA expression upon GSK343 exposure,
normalized to GAPDH, as measured by quantitative RT-PCR. (E) HIV LTR-driven GFP expression in 2D10 cells, as measured by flow cytometry over 96 h.
Treatment with VOR (500 nM) for 24 h served as the positive control. All the data shown represent means, and error bars represent standard deviations of the
means, from three independent experiments.
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HIV LTR expression, and to avoid secondary effects, we exam-
ined early time points (48 h) after knockdown but were unable
to detect proviral induction in EZH2-silenced cells (Fig. 3B).
However, we observed decreased occupancy of key compo-
nents of both Polycomb repressive complexes, PRC1 and PRC2
(Fig. 3C and D). In contrast to EZH2 chemical inhibition, si-
lencing of EZH2 reduced both the H3K27me2 and H3K27me3
marks at the LTR (Fig. 3C), but similar to the effects of
GSK343, H3K27 demethylation did not by itself induce HIV
LTR expression.
H3K27 demethylation of the HIV LTR induced by GSK343
increases the response of the proviral promoter to the HDAC
inhibitor VOR. HDACis and HMT inhibitors (HMTis) have been
reported to synergistically enhance the expression of the latent
HIV genome, although most of these studies were limited by the
use of transformed cell line model systems and nonselective inhib-
itors (16, 18, 19, 45). As we found little effect on latent proviral
expression following demethylation induced by exposure to
GSK343 (Fig. 2), we then asked if the phenotype of the LTR had
been altered, specifically if the HIV LTR was more sensitive to
HDAC inhibition following H3K27 demethylation.
Following the reduction of H3K27me3 induced by 96 h of ex-
posure to GSK343, we assessed the effect of VOR. We observed a
dose-dependent proviral response following increasing exposures
up to 500 nM VOR (Fig. 4A). Demethylation resulted in a 3-fold
increase in LTR-driven GFP expression induced by VOR. How-
FIG 3 EZH2 knockdown decreases H3K27me3 and PRC1 and PRC2 component occupancy in 2D10 cells without an increase in proviral expression. 2D10
cells were treated with either scrambled or EZH2 shRNAs for 48 h according to the Mirus Jurkat Trans-IT transfection reagent protocol. (A) Represen-
tative Western blot showing the effect of silencing of EZH2 on both EZH2 and H3K27me3. The relative quantification of each of the bands is indicated
at the top of each blot. Histone H3 and -tubulin are shown as loading controls. (B) Silencing of EZH2 does not lead to an increase in proviral gene
expression, as measured by flow cytometry. (C) ChIP showing that the occupancy of the PRC2 components EZH2 and EED and H3K27 di- and
trimethylation are reduced selectively at HIV LTR Nuc-1 by shRNA inhibition of EZH2. (D) ChIP showing that the RING1B and BMI1 components of
PRC1 are also reduced at HIV LTR Nuc-1. H3 and H3K9me3 were used, as a control ChIP showed that silencing of EZH2 has no effect on the occupancies
of total histone H3 or on the nonselective H3K9me3 mark. Sc, scrambled shRNA; Sh, EZH2 shRNA. ChIP was performed with the antibodies indicated
at the top of each graph. Error bars represent standard errors of the means from three independent experiments. *, P  0.05; NS, not significant (P  0.05)
(determined by the Student paired t test).
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FIG 4 H3K27 demethylation of the HIV LTR induced by GSK343 increases the response of the proviral promoter to the HDAC inhibitor VOR. (A) In 2D10 cells,
following 96 h of preexposure to 0 to 2.0 M GSK343, a dose-dependent increase in proviral activation following treatment with 350 nM VOR for 24 h is seen
if cells are pretreated with 0.25 M GSK343 (V, equivalent volume of vehicle [0.02% DMSO]; UT, untreated). Means and standard errors of the means were
obtained from three independent experiments. *, P  0.05 for samples treated with VOR and with VOR plus GSK343 (cells treated with 2.0 M); ●, P  0.05 for
samples treated with 2.0 M GSK343 and combined drug treatment; NS, not significant (P  0.05) (determined by a Student paired t test). (B) Enhanced proviral
expression in cells treated with 2 M GSK343 for 96 h (day 4), followed by 24 h of exposure to 500 nM VOR. The samples were assayed by flow cytometry on day
5. The inset shows a FACS overlay, using Flowjo X software, at day 5. Results were compared to those of samples treated with VOR only, and a Student paired t
test was done for three pairs of assays. *, P  0.05. (C) Similar effects were observed when GFP RNA was measured by real-time PCR. Significant increases
following treatment with GSK343 and VOR compared to treatment with VOR alone were determined by using Student paired t tests. Error bars represent
standard errors of the means (n 
 3). *, P  0.05. (D) Effects of inhibitor exposure, as described above for panel B, were determined by ChIP at the HIV LTR for
H3Ac, H3K27me3, and Pol II and phospho-Pol II occupancy, using the respective antibodies at the positions and with the primers indicated. The line diagram
at the bottom represents the 5= HIV LTR and the relative nucleosome positions and primer positions. At Nuc-0, Nuc-1, and the downstream region, the
chromatin marks H3K27me3 and H3Ac and the occupancy of the RNA Pol II and phosphorylated RNA Pol II (marker of processive Pol II) were measured. At
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ever, GSK343 treatment for 72 h did not result in an increased
response to subsequent VOR exposure (data not shown). Of note,
although there was evidence of increased expression in the pres-
ence of VOR at each GSK343 concentration, there was not an
augmented effect of VOR with exposure to the lowest concentra-
tion tested (250 nM). Furthermore, the effect of VOR was not
enhanced by the simultaneous addition of GSK343 (data not
shown). In addition, exposure to GSK343 for 96 h did not fur-
ther increase the LTR response to subsequent VOR exposure (data
not shown).
However, exposure to GSK343 for 96 h is sufficient to sen-
sitize the HIV LTR to a subsequent pulse with VOR. Using
these optimized conditions, we confirmed that HIV RNA in-
duction correlated with GFP induction (Fig. 4B and C). To
further assess the effect of HMTi and HDACi on chromatin
marks, RNA Pol II occupancy, and Pol II processivity (46),
ChIP was performed (Fig. 4D). At both Nuc-1, the nucleosome
adjacent to the transcriptional start site, and the upstream
Nuc-0, treatment with GSK343 led to reduced H3K27me3 lev-
els, and treatment with VOR alone led to increased H3Ac levels,
which was further enhanced by combined treatment with
GSK343. At Nuc-1, RNA Pol II occupancy increased after VOR
exposure with or without GSK343. Consistent with increased
HIV LTR transcription, the processive form of phosphorylated
Pol II (pPol II) exhibited decreased occupancy at Nuc-1, while
increased occupancy was observed (611 Gag) after VOR ex-
posure. This occupancy within the gene body was significantly
enhanced following combined exposure to GSK343 and VOR.
Of note, the level of H3K27me3 remained low under GSK343
treatment conditions even when VOR was added.
In order to test the hypothesis that GSK343 sensitization of the
HIV LTR promoter is a general phenomenon, we tested JQ1, a
small-molecule inhibitor of the bromodomain (BRD) and extra-
C-terminal domain (BET) proteins that can alter epigenetic regu-
lation. First, the minimum JQ1 exposure (50 nM) needed to acti-
vate HIV LTR-mediated GFP expression was established (Fig.
5A). As described above, a reduction of total trimethylated histone
H3K27 was observed upon GSK343 treatment (Fig. 5B). When
2D10 cells were exposed to 2.0 M GSK343 for 96 h and then
treated with 50 nM JQ1 for a further 24 h, we observed enhanced
proviral induction, as measured by GFP expression (Fig. 5C), and
cell-associated HIV RNA (Fig. 5D) levels above those seen follow-
ing exposure to only JQ1. To further assess the effect of the HMTi
and the BET inhibitor (BETi) on chromatin, RNA Pol II occu-
pancy, and Pol II processivity, ChIP was performed (Fig. 5E). At
Nuc-0 and Nuc-1, GSK343 treatment significantly reduced
H3K27me3 and modestly increased H3Ac in combination with
JQ1. While the occupancy of Pol II and pPol II was unchanged at
Nuc-0, their occupancy at Nuc-1 was increased by JQ1 alone or by
combined exposure to GSK343 and JQ1. Again, the increase in
LTR-mediated transcription was associated with increased pPol II
occupancy at the downstream Gag region following JQ1 treat-
ment, which was further enhanced upon combined drug treat-
ment, indicative of processive transcription.
Of note, the recruitment of EZH2 and the level of H3K9me3 at
the different HIV-1 regions (Nuc-0, Nuc-1, and Gag) were also
determined by ChIP in 2D10 cells and were not significantly
changed (not shown).
Occupancy of PRC components and activity of GSK343 at the
HIV LTR in primary resting cells. To extend these studies to
more relevant primary cell models of latent HIV infection, we
established HIV latency in primary CD4 T cells using two previ-
ously reported protocols (40, 47). Components of PRC1 (RING1
and BMI1) and PRC2 (EZH2 and EED) and the silencing mark
H3K27me3 were found at the HIV Nuc-1 region in both the Lewin
CCL19 model (Fig. 6A) and the Bosque-Planelles model (not
shown).
We then validated the effect of 2 M GSK343 in primary un-
infected PBMCs treated for 96 h and confirmed decreases in total
H3K27me3 protein (Fig. 6B) and in promoter occupancy of
H3K27me3 at the cellular MyoD and SAT2 promoters (Fig. 6C).
Again, no effect of GSK343 on cell viability was observed (see Fig.
S2B in the supplemental material). These findings validated the
use of noncycling, primary cell models to study the combined
effect of HDACi and HMTi on HIV latency.
HIV LTR demethylation mediated by an EZH2 inhibitor
prior to exposure to the HDAC inhibitor VOR is associated with
enhanced proviral expression in ex vivo cultures of resting
CD4 T cells. We studied the combined effects of GSK343 and
VOR using the model described previously by Saleh et al. (40),
which was demonstrated to be responsive to VOR. The re-
sponses of this primary cell model to a variety of inducing
stimuli also resemble those of resting CD4 T cells obtained
from HIV-infected patients (48). The design of this experi-
ment, modified slightly from that described by Saleh et al. (40),
is shown in Fig. 7A. Proviral quiescence was established 4 days
after infection, as illustrated by the 10-fold reductions of
viral p24 levels in culture supernatants and of cell-associated
gag RNA levels (Fig. 7B and F).
At day 4, selected cultures were then exposed to 2 M GSK343
for 96 h. ChIP assays with day 8 cell extracts demonstrated a re-
duction of H3K27me3 at the HIV LTR Nuc-1 region and the host
MyoD promoter in treated cultures (Fig. 7G). Again, this effect
was specific, as H3K9me3 was unchanged (Fig. 7G) and, as in
2D10 cells, an increase in H3 acetylation was observed.
Following the exposure of selected cultures to GSK343 and the
validation of demethylation in treated cultures, cells were either
cultured under standard conditions, with 500 nM VOR, or with
PHA as a control to induce maximal proviral expression. Notably,
24 h of exposure to 500 nM VOR induced up to 2.5-fold more HIV
p24 antigen production in cells that had been pretreated with
GSK343 (Fig. 7B to E). This increase was evident at day 9 (Fig. 7D),
Nuc-0, GSK343 treatment reduced H3K27me3 and VOR increased H3Ac levels, while the occupancy of Pol II and pPol II remained unchanged. At Nuc-1, which
is close to the transcription start site, similar observations were made, but the Pol II occupancy was increased, while the pPol II occupancy was reduced by
combined treatment with GSK343 and VOR. At the Gag gene site, in the absence of nearby nucleosomal histones, no effect on acetyl and methyl marks was
observed, but pPol II occupancy increased more by treatment with the combination of GSK343 and VOR than by treatment with VOR alone, indicative of an
augmentation of processive transcription. In panels B to D, error bars represent standard errors of the means from three independent experiments; for each
chromatin mark/occupancy described and to compare the ChIP data obtained with the combined and individual drug treatments, we performed ANOVA of the
4 different treatments (DMSO, GSK343, VOR, and GSK343 plus VOR). All differences noted were significant; , P  0.001. ChIP panels were normalized to H3
levels. The H3 level did not significantly change between the control and treated conditions.
Tripathy et al.
8398 jvi.asm.org August 2015 Volume 89 Number 16Journal of Virology
FIG 5 H3K27 demethylation of the HIV LTR induced by GSK343 also increases the response of the proviral promoter to the BETi JQ1 in 2D10 cells. (A) Dose
response of 2D10 cells to JQ1 at 10 to 1,000 nM, as measured by GFP production. (B) Representative Western blot showing global reduction in H3K27me3 in
whole-cell lysates. Cells were assayed at day 0 (0 h) or were incubated for 5 days (120 h) with either the vehicle control DMSO or 2 M GSK343 for 96 h. In selected
cultures, 50 nM JQ1 was added for the final 24 h of culture. Histone H3 and -tubulin were used as loading controls. (C) Enhanced proviral expression in cells
treated with 2 M GSK343 for 96 h (day 4), followed by 24 h of exposure to 50 nM JQ1. The Student paired t test was done for three pairs of assays. *, P  0.05.
(D) Similar effects were observed when GFP RNA was measured by real-time PCR. Relative fold values of JQ1 versus JQ1 and GSK343 were compared by using
the Student paired t test. Error bars represent standard errors of the means (n 
 3). *, P  0.05. (E) The indicated treatment conditions were also evaluated by
ChIP at the HIV LTR for H3Ac, H3K27me3, Pol II, and phospho-Pol II occupancy using the respective antibodies at the positions and with the primers indicated
in Materials and Methods. The line diagram at the bottom represents the 5=HIV LTR and the relative nucleosome positions and primer positions used for ChIP
assays. At Nuc-0, Nuc-1, and the downstream region, the chromatin marks H3K27me3 and H3Ac and the occupancy of RNA Pol II and phospho-Ser RNA Pol
II (marker of processive transcription or active Pol II) were measured. At Nuc-0, GSK343 treatment reduced H3K27me3 and modestly increased H3Ac when
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following 24 h of exposure to VOR, and although VOR was re-
moved after day 9, increased antigen production was even more
apparent at day 12 (Fig. 7E). Consistent with the increased p24
release into the tissue culture supernatant, an average 2.5-fold
induction of cell-associated HIV gag RNA was also measured in
cultures treated with GSK343 and VOR (Fig. 7F). GSK343 and/or
VOR exposures had no significant effect on cell viability, as mea-
sured by an MTT assay (see Fig. S2C in the supplemental mate-
rial). In a parallel experiment, cells were exposed to a lower con-
centration of VOR (335 nM), and as expected, less p24 production
was induced, although pretreatment with GSK343 still increased
proviral induction (data not shown). Of note, the effect of VOR
was not enhanced by the simultaneous addition of GSK343 (data
not shown).
DISCUSSION
Strahl and Allis postulated that covalent histone modifications
form a “histone code” read by effector proteins to bring about up-
or downregulation of gene expression (49). The array of molecu-
lar mechanisms that first allow the establishment of latent, persis-
tent proviral infection within resting CD4 T cells and then later
allow this transcriptionally quiescent state to be maintained for
months or years in HIV-infected individuals is incompletely un-
derstood. However, it is clear that epigenetic modifications of the
combined with JQ1, while the occupancy of Pol II and pPol II remained unchanged. At Nuc-1, which is close to the transcription start site, similar observations
were made, but the Pol II and pPol II occupancy increased with combined treatments with GSK343 and JQ1. At the downstream Gag gene site, in the absence of
nearby histones, no effect on acetyl and methyl marks was observed, but higher pPol II occupancy than that of Pol II was seen, indicative of processive
transcription. Error bars represent standard errors of the means from three independent experiments. For each chromatin mark/occupancy described and to
compare the ChIP data obtained with the combined and individual drug treatments, we performed ANOVA of the 4 different treatments (DMSO, GSK343, JQ1,
and GSK343 plus JQ1). All differences noted were significant; , P  0.001. ChIP panels were normalized to H3 levels. The H3 level did not significantly change
between the control and treated conditions.
FIG 6 Components of the Polycomb repressive complex occupy the HIV promoter in a latently infected primary T-cell model and validation of EZH2 inhibition
by GSK343 in uninfected PBMCs. PRC1 (RING1B and BMI1) and PRC2 (EZH2 and EED) components occupy the HIV-1 promoter in latently infected primary
T cells. (A) NL4-3-infected primary T cells at day 4 and day 8 postinfection (40), as described in the legend of Fig. 7A. ChIPs for total histone H3, H3K27me3, p50,
H3K27me2, and mock IgG are also shown. Means and standard errors of the means from three independent experiments are displayed. For each chromatin
occupancy described, the Student paired t test was done for 3 pairs of assays. *, P  0.05 for mock IgG-treated versus untreated cells at day 4; ●, P  0.05 for mock
IgG-treated versus untreated cells at day 8; NS, not significant (P  0.05). (B) Representative blot showing a reduction in H3K27me3 in total uninfected PBMCs
at 2 M GSK343 for 96 h. Histone H3 and -tubulin are shown as loading controls. (V, vehicle control [0.02% DMSO]). (C) ChIP changes in the samples
described in panel B. Occupancies of H3K27me3 and control IgG were measured at the host gene promoters SAT2 (heterochromatic gene) and MyoD
(euchromatic region gene). Results were compared with those for DMSO-treated cells by using Student paired t tests. Error bars represent standard errors of the
means (n 
 3). *, P  0.05.
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FIG 7 HIV LTR demethylation mediated by an EZH2 inhibitor prior to exposure to the HDAC inhibitor VOR is associated with enhanced proviral expression
in ex vivo cultures of resting CD4 T cells. (A) Schema for establishment of the primary cell model of HIV latency. Briefly, resting naive CD4 cells were purified
by negative selection using magnetically activated cell sorting (MACS) from the total PBMCs of the healthy donors. These resting cells were treated with 50 nM
CCL19 in the presence of 10 U IL-2 for 2 days. The cells were infected with HIV-1 NL4-3 at day 0, and latency was established at day 4 postinfection. A total of
2 M GSK343 was added at day 4 after latent infection was established. On day 8, GSK343-treated resting T cells were either exposed to 500 nM VOR or left
untreated for a further 24 h. Also, day 8 untreated latently infected cells were treated with 2 g/ml PHA (positive control) for 24 h. The effects were measured on
days 9 and 12. Samples were washed on day 9 and kept in complete medium with 10 U IL-2/ml until the time of harvest at day 12. (B to E) Graphs showing viral
p24 production in supernatants measured by a p24 ELISA at the times indicated. Means and standard errors of the means are from three independent
experiments compared to the untreated control conditions; p24 values were normalized to 1 for the untreated control. UT, infected but untreated; PRE, before
washing to remove the viral inoculum; POST, after washing to remove the viral inoculum; V, VOR; 343, GSK343. D0 refers to day 0 postinfection. The Student
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HIV LTR, most notably histone acetylation and methylation, con-
tribute to the maintenance of the latent proviral state (2).
While DNA methylation does not appear to play a critical role
in HIV silencing (50), acting by promoting histone methylation,
Suv39H1 (17), G9a (19), and EZH2 (18) have been reported to
participate in the maintenance of HIV latency. This activity of
these enzymes was further validated by using pharmacological
inhibitors such as BIX01294 (19), chaetocin (16, 45), and
3-deazaneplanocin A (DZNep) (18), alone or in combination
with HDACis (16, 18, 19, 45, 51). However, these studies have
serious limitations, as they were performed in either cycling,
transformed T-cell line models of HIV latency (16, 18, 19, 45) or
bulk PBMCs and resting CD4 T cells isolated from HIV-positive
(HIV) aviremic patients (45), and the inhibitors used in these
studies were either not highly selective or used at concentrations
that allowed nonselective effects.
Following the demonstration that HDACis could disrupt HIV
latency, the combined use of inhibitors of histone methylation
and histone deacetylation to synergistically reactivate the expres-
sion of quiescent provirus within latently infected resting CD4 T
cells was considered (45). Although plausible, it remained unclear
how the modulation of an epigenetic mark at the same histone
residue would necessarily augment proviral expression beyond
that achieved by maximal inhibition of deacetylation or methyl-
ation.
Therefore, before such a combination epigenetic approach,
with the attendant risks of increased off-target toxic effects, is to be
tested in animal models or human studies, evidence of the efficacy
of combined therapy should be obtained with the most advanced
and relevant experimental systems. Therefore, we attempted to
address these limitations by (i) establishing exposure to an EZH2i
that allows H3K27 demethylation but does not by itself result in
HIV RNA expression; (ii) using the EZH2/EZH1 inhibitor
GSK343, which is selective in primary cell systems (39); and (iii)
performing studies using resting primary T-cell models of latency.
First, to validate the study of an EZH2 inhibitor, we estab-
lished the presence of PRC2 and EZH2 itself in the 2D10 cell
line. Although not unexpected, we also detected components of
PRC1 occupying the HIV LTR in the model systems that we
studied. Although further study of the activity and regulation
of PRC1 at the HIV LTR is needed, taken together, the results of
EZH2 inhibitor (unpublished data) and knockdown experi-
ments suggest that PRC1 occupancy may be dependent on
PRC2 occupancy and/or EZH2 activity.
To facilitate studies with the more demanding primary cell
systems, we then established the appropriate exposure conditions
to study the effect of the EZH2 inhibitor GSK343. We found that
the action of GSK343 to remove the H3K27me3 mark at the crit-
ical HIV LTR Nuc-1 site and at two host gene loci was gradual,
requiring 96 h of inhibitor exposure to markedly reduce the levels
of trimethylation. Demethylation was selective, as there was no
significant change in H3K9 trimethylation. While demethylation
modestly increased the levels of acetylated H3 at the HIV Nuc-1
region at higher GSK343 concentrations over 96 h, it is critical to
note that no significant increase in HIV LTR expression, as mea-
sured by both HIV RNA transcripts and the production of the
GFP marker protein, was detected.
Small-molecule inhibitor studies were corroborated by exper-
iments using shRNA inhibition of EZH2, similarly showing dem-
ethylation and reduced occupancy of components of both PRC2
and PRC1. Of note, previous work found that short hairpin RNA
knockdown of EZH2 in 2D10 and E4 cell lines (18) resulted in the
activation of LTR expression. The studies presented here utilized
transient knockdown for only 48 h, measuring a more immediate
effect of the loss of EZH2 activity.
We then tested the ability of GSK343, which did not signifi-
cantly increase HIV LTR expression by itself, to sensitize the viral
promoter to the inducing effect of the HDAC inhibitor VOR. The
demonstration of the added value of such a combined effect is at
the heart of the concept of combinations of “latency-reversing
agents.” Of interest, minimal exposure to VOR (250 nM) had a
modest effect (Fig. 4A) on LTR expression, which was unaffected
by demethylation induced by GSK343. However, demethylation
markedly sensitized the HIV LTR to exposures to higher concen-
trations of VOR, with a 3-fold increase of expression over that
induced by VOR alone (8% to 26% GFP expression at 500 nM)
(Fig. 4A). ChIP assays (Fig. 4D) documented that demethylation
was induced by GSK343 at both Nuc-1, near the LTR transcrip-
tional start site, and Nuc-0, in the enhancer region. Furthermore,
the exposure to VOR resulted in acetylation at these sites, but
acetylation was augmented if preceded by demethylation by
GSK343. Of note, simultaneous exposure to VOR and GSK343 did
not enhance the effect of VOR on LTR expression. While dem-
ethylation alone did not increase Pol II occupancy at Nuc-0, poly-
merase occupancy was increased by VOR, with or without dem-
ethylation. Pol II processivity, as marked by decreased occupancy
of phosphorylated Pol II and increased occupancy in the down-
stream gene body, was increased by VOR and further augmented
by demethylation.
A variety of agents are under study for their potential to effec-
tively and safely reverse HIV latency. Among them, BET inhibitors
have been suggested to have latency-reversing effects in some
model systems, although they do not appear to allow the recovery
of latent provirus from resting CD4 T cells of aviremic patients as
efficiently as HDACis (52–54). However, it is remarkable that
demethylation of the HIV LTR sensitized the proviral promoter to
the effects of JQ1 (Fig. 5), just as it did to the HDACi VOR.
Some previous studies of the activity of EZH2 at the HIV LTR
have been complicated by the use of models utilizing cycling cells,
notably transformed cell lines. The stability of epigenetic marks
and the activities required to maintain them in such cells are likely
to differ from those in primary, resting CD4 T cells, the primary
reservoir of latent HIV infection. Therefore, it was extremely im-
portant to extend these studies to ex vivo cultures of primary rest-
paired t test was done for paired samples as indicated, and values are from three experiments (n 
 3). ● or *, P  0.05. (F) Enhanced viral production was also
measured as cell-associated viral gag RNA fold changes compared to untreated infected samples for each time point group (days 0, 4, 8, 9, and 12) by using
real-time PCR. The Student paired t test was done for the paired samples as indicated, and values from three experiments are shown (n 
 3). ● or *, P  0.05. (G)
ChIP assay of the cellular promoter MyoD and viral promoter HIV LTR Nuc-1 was performed for mock (IgG) and the H3K27me3, H3K9me3, and H3Ac
chromatin marks for untreated and GSK343-treated samples on days 4 and 8. ChIP panels were normalized to H3 levels. The H3 level did not significantly change
between the control and treated conditions. Results were compared with those for untreated day 4 chromatin by using Student paired t tests. Error bars represent
standard errors of the means (n 
 3). *, P  0.05.
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ing cells. We documented the occupancy of PRC2 and PRC1 com-
ponents in two primary cell models of latent HIV infection (Fig.
6A) (not shown) and the kinetics of demethylation induced by
GSK343 in primary cells (Fig. 6C and D). We then modified the
primary cell model protocol described previously by Saleh et al.
(40) to allow a period of pretreatment with GSK343, documenting
demethylation at both the proviral promoter as well as a host gene,
with modest increases in acetylation as well but without an in-
crease in proviral gene expression or HIV p24 antigen production
(Fig. 7). It was in this setting that we were able to observe a clear
sensitization of the proviral promoter within resting, primary
cells, mediated by demethylation induced by GSK343, to the sub-
sequent HDACi effect of VOR. Importantly, this augmented dis-
ruption of HIV latency was achieved without inducing markers of
cellular activation (data not shown).
In summary, it is widely believed that if treatments to eradicate
HIV infection can be developed, they will involve a combination of
interventions designed to disrupt latent infection and then allow in-
fected cells to be targeted and cleared. HDAC inhibitors have shown
some promise in the disruption of HIV latency in humans. However,
in vitro evidence suggests that the effects of HDACis might be incom-
plete or insufficiently potent to allow complete ablation of persistent
infection (33, 34). Combination approaches for the reversal of HIV
latency have been demonstrated in vitro, but thus far, none appear
safe enough to test in the clinic.
HMTis are entering clinical trials, and early reports suggest
that such inhibitors may be safely administered with the signifi-
cant caveat that, as was true with HDACis, current testing is on-
going in patients suffering from malignancies (55). Furthermore,
as both HMTis and HDACis target cellular processes, their poten-
tial effects on immune activity must be examined, as eradication
strategies will likely require unimpeded immune function to clear
infected cells.
The development of effective latency-reversing agents and res-
ervoir depletion strategies is challenging given the extraordinary
health benefits of ART. The demonstration that EZH2 inhibition
can sensitize HIV hidden in the persistent reservoir of infection
within primary, resting CD4 T cells to the latency-reversing ef-
fects of an HDAC inhibitor provides a proof-of-principle for this
type of combination antilatency therapy. Such combinations
should be considered for further study in animal model systems
or, if safe and practical, in clinical studies.
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